p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.
p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy. Leuk Lymphoma. 2009 Oct; 50(10):1597-605.
-
Adult
-
Aged
-
Aged, 80 and over
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Combined Chemotherapy Protocols
-
Biomarkers, Tumor
-
Bone Marrow Examination
-
Combined Modality Therapy
-
Cyclophosphamide
-
Female
-
Follow-Up Studies
-
Gene Expression Regulation, Leukemic
-
Genes, p53
-
Humans
-
Immunohistochemistry
-
Leukemia, Lymphocytic, Chronic, B-Cell
-
Male
-
Middle Aged
-
Prognosis
-
Rituximab
-
Somatic Hypermutation, Immunoglobulin
-
Survival Analysis
-
Tumor Suppressor Protein p53
-
Vidarabine
-
Young Adult
-
ZAP-70 Protein-Tyrosine Kinase